The goal of the experimental animal core is to provide relevant mouse and rat models for studying the development of tumors in the colon and the apoptotic pathway. These systems will provide models for evaluating nutritional and other extracellular factors such as hormones or bile acids that may affect the apoptotic pathway and for evaluating the effects of potential chemopreventive agents. Included in these models are mice that have defective genes, p53, BCl2, and APC which have been shown in both human and mouse colon tumors to be involved in the oncogenesis of these tumors. These models allow for a more targeted approach for identification of molecular targets for chemoprevention.
The specific aims of the core are: 1) to provide relevant murine models to study colon oncogenesis and the apoptotic pathway; 2) to provide treatments, carcinogens or dietary, that promote tumor development in each appropriate model; 3) to administer chemopreventive agents and 4) to provide fresh tissues from the animal study protocols to each project. The experimental animal core provides a means in which animals needed for studies by four different projects can be shared and the results of the studies are combinative. The advantages to having a experimental animal core are: less animals are needed than if each project performed the animal studies by themselves; there is uniformity and quality control in carrying out the study protocols across each project; data generated from each study is comparable given that the information is generated from the same sources with common controls and, the core allows us to examine multiple rodent models of colon cancer that would otherwise be unaffordable. In this program, both normal and neoplastic colonic tissues will be analyzed.
|Raj, K P; Zell, J A; Rock, C L et al. (2013) Role of dietary polyamines in a phase III clinical trial of difluoromethylornithine (DFMO) and sulindac for prevention of sporadic colorectal adenomas. Br J Cancer 108:512-8|
|Rial, Nathaniel S; Zell, Jason A; Cohen, Alfred M et al. (2012) Clinical end points for developing pharmaceuticals to manage patients with a sporadic or genetic risk of colorectal cancer. Expert Rev Gastroenterol Hepatol 6:507-17|
|Laukaitis, Christina M; Erdman, Steven H; Gerner, Eugene W (2012) Chemoprevention in patients with genetic risk of colorectal cancers. Colorectal Cancer 1:225-240|
|Laukaitis, Christina M; Gerner, Eugene W (2011) DFMO: targeted risk reduction therapy for colorectal neoplasia. Best Pract Res Clin Gastroenterol 25:495-506|
|Gerner, Eugene W; Meyskens Jr, Frank L (2009) Combination chemoprevention for colon cancer targeting polyamine synthesis and inflammation. Clin Cancer Res 15:758-61|
|Rial, Nathaniel S; Lazennec, Gwendal; Prasad, Anil R et al. (2009) Regulation of deoxycholate induction of CXCL8 by the adenomatous polyposis coli gene in colorectal cancer. Int J Cancer 124:2270-80|
|Zell, Jason A; Pelot, Daniel; Chen, Wen-Pin et al. (2009) Risk of cardiovascular events in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas. Cancer Prev Res (Phila) 2:209-12|
|Ashbeck, Erin L; Jacobs, Elizabeth T; Martínez, María Elena et al. (2009) Components of metabolic syndrome and metachronous colorectal neoplasia. Cancer Epidemiol Biomarkers Prev 18:1134-43|
|Zell, Jason A; Ziogas, Argyrios; Ignatenko, Natalia et al. (2009) Associations of a polymorphism in the ornithine decarboxylase gene with colorectal cancer survival. Clin Cancer Res 15:6208-16|
|Feldman, Rebecca; Martinez, Jesse D (2009) Growth suppression by ursodeoxycholic acid involves caveolin-1 enhanced degradation of EGFR. Biochim Biophys Acta 1793:1387-94|
Showing the most recent 10 out of 88 publications